Old Web
English
Sign In
Acemap
>
authorDetail
>
L. Dima
L. Dima
Bayer HealthCare Pharmaceuticals
Trk receptor
Medicine
Cancer research
Adverse effect
Internal medicine
5
Papers
4
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.
2021
Journal of Clinical Oncology
Jessica J. Lin
S. Kummar
Daniel Shao-Weng Tan
Ulrik Lassen
Serge Leyvraz
Yongmei Liu
Victor Moreno
Jyoti D. Patel
Lee S. Rosen
Benjamin Maurice Solomon
Ricarda Norenberg
L. Dima
Nicoletta Brega
Lin Shen
Alexander Drilon
Show All
Source
Cite
Save
Citations (1)
Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.
2021
Journal of Clinical Oncology
Sébastien Perreault
Cornelis M. van Tilburg
Birgit Geoerger
Karsten Nysom
Ingrid Øra
Igor T. Gavrilovic
Ricarda Norenberg
L. Dima
Esther De La Cuesta
Alexander Drilon
François P Doz
Show All
Source
Cite
Save
Citations (2)
1